Your browser doesn't support javascript.
Persistence of Antibody and Cellular Immune Responses in Coronavirus Disease 2019 Patients Over Nine Months After Infection.
Yao, Lin; Wang, Guo-Lin; Shen, Yuan; Wang, Zhuang-Ye; Zhan, Bing-Dong; Duan, Li-Jun; Lu, Bing; Shi, Chao; Gao, Yu-Meng; Peng, Hong-Hong; Wang, Guo-Qiang; Wang, Dong-Mei; Jiang, Ming-Dong; Cao, Guo-Ping; Ma, Mai-Juan.
  • Yao L; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Beijing, China.
  • Wang GL; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Beijing, China.
  • Shen Y; Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
  • Wang ZY; Dezhou Municipal Center for Disease Control and Prevention, Dezhou, China.
  • Zhan BD; Quzhou Municipal Center for Disease Control and Prevention, Quzhou, China.
  • Duan LJ; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Beijing, China.
  • Lu B; Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
  • Shi C; Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
  • Gao YM; Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
  • Peng HH; Wuxi Municipal Center for Disease Control and Prevention, Wuxi, China.
  • Wang GQ; Dezhou Municipal Center for Disease Control and Prevention, Dezhou, China.
  • Wang DM; Dezhou Municipal Center for Disease Control and Prevention, Dezhou, China.
  • Jiang MD; Dezhou Municipal Center for Disease Control and Prevention, Dezhou, China.
  • Cao GP; Quzhou Municipal Center for Disease Control and Prevention, Quzhou, China.
  • Ma MJ; State Key Laboratory of Pathogen and Biosecurity, Institute of Microbiology and Epidemiology, Beijing, China.
J Infect Dis ; 224(4): 586-594, 2021 08 16.
Article in English | MEDLINE | ID: covidwho-1367023
ABSTRACT

BACKGROUND:

The duration of humoral and T and B cell response after the infection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains unclear.

METHODS:

We performed a cross-sectional study to assess the virus-specific antibody and memory T and B cell responses in coronavirus disease 2019 (COVID-19) patients up to 343 days after infection. Neutralizing antibodies and antibodies against the receptor-binding domain, spike, and nucleoprotein of SARS-CoV-2 were measured. Virus-specific memory T and B cell responses were analyzed.

RESULTS:

We enrolled 59 patients with COVID-19, including 38 moderate, 16 mild, and 5 asymptomatic patients; 31 (52.5%) were men and 28 (47.5%) were women. The median age was 41 years (interquartile range, 30-55). The median day from symptom onset to enrollment was 317 days (range 257 to 343 days). We found that approximately 90% of patients still have detectable immunoglobulin (Ig)G antibodies against spike and nucleocapsid proteins and neutralizing antibodies against pseudovirus, whereas ~60% of patients had detectable IgG antibodies against receptor-binding domain and surrogate virus-neutralizing antibodies. The SARS-CoV-2-specific IgG+ memory B cell and interferon-γ-secreting T cell responses were detectable in more than 70% of patients.

CONCLUSIONS:

Severe acute respiratory syndrome coronavirus 2-specific immune memory response persists in most patients approximately 1 year after infection, which provides a promising sign for prevention from reinfection and vaccination strategy.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Immunity, Cellular / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Topics: Long Covid / Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Antibodies, Neutralizing / COVID-19 / Immunity, Cellular / Antibodies, Viral Type of study: Observational study / Randomized controlled trials Topics: Long Covid / Vaccines / Variants Limits: Adult / Female / Humans / Male / Middle aged Language: English Journal: J Infect Dis Year: 2021 Document Type: Article Affiliation country: Infdis